CIK 0000906709 · Pharmaceutical Preparations (SIC 2834) · Nasdaq · incorporated in DE · fiscal year ends 12/31
| FY2025 | FY2024 | FY2023 | FY2022 | |
|---|---|---|---|---|
| Revenue (USD) | 55.2 M | 90.1 M | 92.1 M | |
| Net income (USD) | -444.4 M | |||
| Diluted EPS (USD/shares) | -9.73 | -1.45 | -1.97 |
| Filed | Form | Description | Period |
|---|---|---|---|
| 2026-10-20 | S-8 | REGISTRATION STATEMENT | |
| 2026-10-01 | 8-K | CURRENT REPORT items 7.01,9.01 | 2026-10-01 |
| 2026-09-28 | SCHEDULE 13G/A | SCHEDULE 13G/A | |
| 2026-09-25 | 4 | 4 | 2026-09-23 |
| 2026-09-25 | 4 | 4 | 2026-09-23 |
| 2026-09-25 | 4 | 4 | 2026-09-23 |
| 2026-09-25 | 4 | 4 | 2026-09-23 |
| 2026-09-25 | 4 | 4 | 2026-09-23 |
| 2026-09-25 | 8-K | CURRENT REPORT items 8.01 | 2026-09-24 |
| 2026-09-08 | 8-K | CURRENT REPORT items 7.01,9.01 | 2026-09-08 |
| 2026-08-20 | 4 | 4 | 2026-08-18 |
| 2026-08-20 | 4 | 4 | 2026-08-18 |
| 2026-08-18 | 144 | 144 | |
| 2026-08-18 | 144 | 144 | |
| 2026-08-14 | SCHEDULE 13G/A | SCHEDULE 13G/A | |
| 2026-08-14 | S-8 | REGISTRATION STATEMENT | |
| 2026-08-14 | SCHEDULE 13G/A | SCHEDULE 13G/A | |
| 2026-08-14 | 10-Q | 10-Q | 2026-06-30 |
| 2026-08-13 | 8-K | CURRENT REPORT items 2.02,9.01 | 2026-08-13 |
| 2026-07-31 | SCHEDULE 13G | SCHEDULE 13G | |
| 2026-07-29 | SCHEDULE 13G | SCHEDULE 13G | |
| 2026-07-24 | 4 | 4 | 2026-07-24 |
| 2026-07-24 | 4 | 4 | 2026-07-24 |
| 2026-07-02 | 4 | 4 | 2026-06-30 |
| 2026-06-30 | 144 | 144 |
Forms on file (last 1,000): 4 529, 8-K 162, SC 13G/A 62, 144 54, 10-Q 34, SCHEDULE 13G/A 17, 4/A 15, S-8 12. Source: SEC EDGAR, as filed; this page is public data and not investment advice.
GET https://store.agentexchange.work/gw/filings/company?ticker=NKTR (0.002 USD), /gw/filings/filings?ticker=NKTR&form=8-K, /gw/filings/facts?ticker=NKTR&concept=Revenues, full-text /gw/filings/search?q=.... Pay per call in USDC (x402) or with a 19 USD card key for 1,000 calls. Catalogue · llms.txtUpdated from EDGAR within 30 minutes of a filing. Agent Exchange